[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7929-7937

  McCluskey, Anthony G ^a   Boyd, Marie ^a   Ross, Susan C ^a   Cosimo, Emilio ^a   Clark, Anne Marie ^a   Angerson, Wilson J ^a   Gaze, Mark N ^b   Mairs, Robert J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; DNA FRAGMENT; DNA TOPOISOMERASE INHIBITOR; NORADRENALIN TRANSPORTER; SODIUM CHLORIDE; TOPOTECAN; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER INHIBITION; CLONOGENESIS; COLONY FORMING UNIT; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIZATION; THROMBOCYTE COUNT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CATTLE; GENETIC TRANSFECTION; GLIOMA; METABOLISM; NEOPLASM; PATHOLOGY; TIME; TUMOR CELL LINE;

3-IODOBENZYLGUANIDINE; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; DNA FRAGMENTATION; DNA, COMPLEMENTARY; GLIOMA; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS; TOPOTECAN; TRANSFECTION;

EID: 27744605161     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0982     Document Type: Article

References (49)

1. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
2. 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003;25:769-73.
3. 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003;98:239-48.
4. Jaques S, Jr., Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of mete-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26:539-46.
5. Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with 1-131 meta-iodobenzyl-guanide. Cancer 1991;67:922-8.
6. 131I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. 3rd ed. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC, editors. Advances in neuroblastoma research. New York: Wiley-Liss; 1991. p. 439-45.
7. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.
8. Gaze MN, Wheldon TE. Radiolabelled mIBG in the treatment of neuroblastoma. Eur J Cancer 1996;32:93-6.
9. 131I]MIBG) in combination with other agents. Eur J Cancer 1999;8:1171-4.
10. Vassal G, Pondarré C, Capelli C, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 1997;33:2011-5.
11. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumours: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998;20:315-8.
12. Miyamoto S, Huang TT, Wuerzberger-Davis S, et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci 2000;922:274-92.
13. Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK and F 104864). Cancer Res 1991;51:5813-6.
14. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of topoisomerase I inhibitors with radiation in c/s-diamminedichloroplatinum(II)- sensitive and -resistant cells in vitro and in the FSaIIC fibrosarcoma in vivo. Int J Cancer 1993;53:118-23.
15. Hennequin C, Giocanti N, Balosso J, Favaudon V. Interaction of ionising radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 1994;54:1720-8.
16. Marchesini R, Colombo A, Caserini C, et al. Interaction of ionizing radiation with topotecan in two human cell lines. Int J Cancer 1996;66:342-6.
17. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Concentration and timing dependence enhancement between topotecan, a topoisomerase I inhibitor and ionising radiation. Int J Radiat Oncol Biol Phys 1996;36:361-8.
18. Kohara H, Tabata M, Kiura K, et al. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxy-camptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 2002;8:287-92.
19. Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 1996;67:95-100.
20. Armour A, Cunningham SH, Gaze MN, et al. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 1997;75:470-6.
21. Mairs RJ, Cunningham SH, Boyd M, Carlin S. Applications of gene transfer to targeted radiotherapy. Curr Pharm Des 2000;6:1419-32.
22. Beidler JL, Roffler-Tarlov S, Schwachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751-7.
23. 131l]meta- iodobenzylguanidine. Gene Ther 1999;6:1147-52.
24. 123I] MIBG. J Lab Comp Radiopharm 1999;42:653-61.
25. 131l]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 2004;1:50-7.
26. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of meta-iodo-benzyl guanidine by the neuroblastoma cell line NB1-G. Br J Cancer 1991;64:293-5.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. New York: Academic Press; 1991. p. 61-102.
29. Olive PL, Banath JP, Durand RE. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 1990;82:779-83.
30. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
31. Rutgers M, Buitenhuis CKM, Hoefnagel CA, Voute PA, Smets LA. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy. Int J Cancer 2000;87:412-22.
32. Morton DB, Griffiths PHM. Endpoints in animal study protocols. Vet Rec 1985;116:431-43.
33. 131I-meta-iodo-benzyl guanidine in two neuroblastoma xenografts. Br J Radiol 1994;67:573-8.
34. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999;5:3617-31.
35. Graham GJ, Freshney MG. CFU-A assay for measurement of the anti-proliferative effects of chemokines on murine early haemopoietic progenitors. In: Proudfoot AEI, Wells TNC, Power CA, editors. Chemokine protocols. Totowa (NJ): Humana Press, Inc.; 2000. p. 179-89.
36. Graham GJ, Wright EG. Haemopoietic stem cells: their heterogeneity and regulation. Int J Exp Pathol 1997;78:197-218.
37. Livingstone A, Mairs RJ, Russell J, O'Donoghue J, Gaze MN, Wheldon TE. N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment. Eur J Cancer 1994;30:382-9.
38. Boyd M, Livingstone A, Wilson LE, et al. The dose response relationship for radiation induced mutations at micro- and minisatellite loci in human somatic cells in culture. Int J Radiat Biol 2000;76:169-76.
39. Keshelava N, Groshen S, Reynolds P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000;45:1-8.
40. Dubois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-60.
41. Kramer K, Kushner BH, Cheung N-KV. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 2003;25:601-5.
42. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-9.
43. Lamond JP, Metha MP, Boothman DA. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: a report of a synergistic effect between topotecan and radiation. J Neuro-oncol Biol Physiol 1996;30:1-6.
44. Ng B, Kramer E, Liebes L, et al. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast carcinoma xenografts. Cancer Res 2001;61:2996-3001.
45. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 1993;14:2341-51.
46. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group Study. J Clin Oncol 2004;22:1398-403.
47. Forouzannia A, Schiller J, Berlin J, et al. A phase I study of topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer 2004;44:111-9.
48. Perez-Martinez A, Quintero V, Vicent MG, Sevilla J, Diaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2004;67:101-6.
49. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitiser in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:191-5.